MGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MacroGenics Inc (MGNX) does not present a strong buy opportunity for a beginner investor with a long-term focus at this time. While the stock shows some positive financial growth in revenue and bullish moving averages, the lack of significant trading signals, weak options sentiment, and declining profitability metrics such as net income and EPS make it less compelling for immediate investment.
The stock's technical indicators show mixed signals. The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 66.586. However, the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting a positive trend. The stock is trading near its resistance level (R1: 3.197), which could limit further upside in the short term.
Revenue increased significantly by 113.03% YoY in Q4 2025, and gross margin improved to 75.47%, up 5.36% YoY. Analysts have raised the price target to $4 and maintain an Overweight rating, citing potential upside from antibody-drug conjugate data in 2026.
Net income dropped by 8.21% YoY, and EPS declined by 12.00% YoY, indicating profitability challenges. No recent news or significant insider or hedge fund activity to drive short-term momentum. Congress trading data is also absent.
In Q4 2025, revenue grew significantly by 113.03% YoY to $41.23 million, but net income declined to -$14.15 million (-8.21% YoY), and EPS dropped to -0.22 (-12.00% YoY). Gross margin improved to 75.47%, up 5.36% YoY, indicating better operational efficiency.
Barclays raised the price target from $3 to $4 and maintains an Overweight rating. The firm sees potential upside from the company's antibody-drug conjugate data in 2026, suggesting a longer-term positive outlook.
